<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Document</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.9.0/css/all.min.css" integrity="sha512-q3eWabyZPc1XTCmF+8/LuE1ozpg5xxn7iO89yfSOd5/oKvyqLngoNGsx8jq92Y8eXJ/IRxQbEC+FGSYxtk2oiw==" crossorigin="anonymous" referrerpolicy="no-referrer" />
    <!-- Bootstrap CDN -->
    <link rel="stylesheet" href="css/bootstrap.min.css">
    <!-- Main CSS -->
    <link rel="stylesheet" href="css/style.css">

</head>

<body>

    <div class="fixedHeight">
        <div class="right_shape">
            <a href="../page8/index.html" class="cross_icon_close">
                <img src="img/cross_icon.svg" alt="">
            </a>
            <img src="img/right_silver_shape.png" style="zoom: .5;" alt="">
        </div>
        <div class="container_xxl container-xxl py-5 z_index9">
            <div class="pt-2">
                <div class="w_heading">
                    <h3 class="txt_orange GothamMedium pt-1">IXAZOMIB (NINLARO) DISCONTINUATION <br> AND DOSE REDUCTION DATA FROM TWO <br> REAL-WORLD STUDIES<sup class="h5">2,3</sup></div></h3>
                </div>
                <div class="w-75">
                    <div class="p19_table_row_border_t">
                        <h4 class="GothamBook fst-italic txt_blue mb-4 pt-2">Real-World Evidence</h4>
                    </div>

                    <div>
                        <div class="text-center">
                            <p class="mb-1 GothamLight txt_silver fs-13"><span class="GothamMedium fs-12">Hajek et al:</span>  INSIGHT-MM and RMG<sup>2</sup></p>
                        </div>
                        <div class="p9_table_1st_row py-2 text-center border_bottom_orange_1">
                            <p class="mb-0 txt_blue GothamMedium fs-11">Drug discontinuation and dose reduction rates due to documented AEs <br> were similar between Ixazomib (NINLARO) and lenalidomide</p>
                        </div>
                    </div>
                </div>
                <div class="d-flex">
                    <div class="w-75">
                        <div class="d-flex justify-content-between imgCircleCtrl">
                            <div class="w-50 d-flex flex-wrap">
                                <div class="p32_rotate_text">
                                    <p>DRUG DISCONTINUATIONS</p>
                                </div>
                                <div class="p32_graph_w_40 me-auto">
                                    <div class="p32_graph_heading">Ixazomib <br> (NINLARO)</div>
                                    <img src="img/p32_graph_img_blue_1.png" class="w-100" alt="">
                                </div>
                                <div class="p32_graph_w_40 me-auto">
                                    <div class="p32_graph_heading">Lenalidomide</div>
                                    <img src="img/p32_graph_img_blue_2.png" class="w-100" alt="">
                                </div>
                                <div class="w-100 text-center GothamMedium fs-11 py-1 txt_silver"><span class="p32_before_blue"></span> Patients discontinued regimen <br> due to documented AEs</div>
                            </div>
                            
                            <div class="w-50 d-flex flex-wrap">
                                <div class="p32_rotate_text">
                                    <p>DOSE REDUCTIONS</p>
                                </div>
                                <div class="p32_graph_w_40 me-auto">
                                    <div class="p32_graph_heading">Ixazomib <br> (NINLARO)</div>
                                    <img src="img/p32_graph_img_1.png" class="w-100" alt="">
                                </div>
                                <div class="p32_graph_w_40 me-auto">
                                    <div class="p32_graph_heading">Lenalidomide</div>
                                    <img src="img/p32_graph_img2.png" class="w-100" alt="">
                                </div>
                                <div class="w-100 text-center GothamMedium py-1 txt_silver fs-11"><span class="p32_before_orange"></span> Patients required dose reduction <br> due to documented AEs*</div>
                            </div>
                        </div>
                    </div>
                    <div class="page5_btns_sm mb-1 d-flex justify-content-center align-items-end ps-5 controllBtnPosition">
                        <a href="../page8/index.html" class="text-uppercase btn_sm_plus height_fit_content">
                            <span><i class="fas fa-plus"></i></span>
                            <p class="mb-0 position-relative">SEE STUDY DESIGN</p>
                        </a>
                    </div>
                </div>

                <div class="d-flex flex-wrap">
                    <div class="w-75">
                        <div class="text-center mtUp">
                            <p class="txt_silver GothamLight fs-13"><span class="GothamMedium fs-12">Chari et al:</span> Optum’s EHR database, US<sup>3</sup></p>
                            <div class="p9_table_1st_row fs-12 py-2 text-center border_bottom_orange_1">
                                <p class="mb-0 txt_silver GothamMedium">Risk of component discontinuation</p>
                            </div>

                            <div class="p9_table">                
                                <div class="d-flex align-items-center justify-content-between py-2 pe-4 p9_table_nrow">
                                    <div class="w-25 txt_blue GothamBlack text-start"></div>
                                    <div class="w-25 txt_orange GothamBold text-center">IRd vs KRd</div>
                                    <div class="w-25 txt_silver GothamBold text-center">IRd vs VRd</div>
                                    <div class="w-25 txt_silver_light GothamBlack text-center">KRd vs VRd</div>
                                </div>
                                <div class="d-flex align-items-center justify-content-between py-2 pe-4 p9_table_nrow">
                                    <div class="w-25 txt_blue GothamBold text-start">PI component</div>
                                    <div class="w-25 txt_orange GothamBold text-center">HR: 0.65 <br> <span class="fst-italic">P=0.0034</span></div>
                                    <div class="w-25 txt_silver GothamBold text-center">HR: 0.62 <br> <span class="fst-italic">P=0.0003</span></div>
                                    <div class="w-25 txt_silver_light GothamBold text-center">HR: 0.94 <br> <span class="fst-italic">P>0.05</span></div>
                                </div>
                                <div class="d-flex align-items-center justify-content-between py-2 pe-4 p9_table_nrow p13_table">
                                    <div class="w-25 txt_blue GothamBold text-start">Lenalidomide component</div>
                                    <div class="w-25 txt_orange GothamBold text-center">HR: 0.64 <br> <span class="fst-italic">P=0.0015</span></div>
                                    <div class="w-25 txt_silver GothamBold text-center">HR: 0.75 <br> <span class="fst-italic">P=0.0312</span></div>
                                    <div class="w-25 txt_silver_light GothamBold text-center">HR: 1.18 <br> <span class="fst-italic">P>0.05</span></div>
                                </div>
                            </div>
                        </div>
                    </div>
                    <div class="page5_btns_sm mb-1 d-flex justify-content-center align-items-end ps-5 controllBtnPosition-2">
                        <a href="../page11/index.html" class="text-uppercase btn_sm_plus height_fit_content">
                            <span><i class="fas fa-plus"></i></span>
                            <p class="mb-0 position-relative">SEE STUDY DESIGN</p>
                        </a>
                    </div>
                    <div class="w-100 py-2">
                        <p class="GothamLight mb-0 d-flex align-items-center"><img src="img/list_blue_icon.svg" class="me-2" alt=""> Risk of discontinuation was significantly lower for the Ixazomib (NINLARO) + Rd vs KRd</p>
                    </div>
                </div>
        </div>
        <div style="height: 120px;"></div>
        <div class="footer_page1 bg-transparent">
            <div class="container_xxl container-xxl">
                <div class="footer_inner1 footer_inner2">
                    <p class="GothamBold fs-12">
                        Cross-trial comparisons are potentially confounded by differences in trial design and study population. Statistical significance is not implied when comparing across MM1 and Real-world evidence.
                    </p>
                    <p class="GothamLight fs_12">*Patients who required dose reduction may have also subsequently discontinued treatment.
                        AE = adverse event; EHR = electronic health record; HR = hazard ratio; KRd = carfilzomib + REVLIMID® (lenalidomide) + dexamethasone; PI = proteasome inhibitor; IRd = Ixazomib (NINLARO) + REVLIMID®
                        (lenalidomide) + dexamethasone; RMG = Registry of Monoclonal Gammopathies; US = United States; VRd = bortezomib + REVLIMID® (lenalidomide) + dexamethasone.</p>
                </div>
            </div>
            <div class="footer_inner_nav1 bg-transparent footer_inner_nav1_modified_reff">
                <ul class="mb-1 me-1">
                    <li>
                        <a href="../page4/index.html"><img src="img/page_1_footer_icon_1.svg" alt=""></a>
                    </li>
                    <li>
                        <a href="https://onetakeda.app.box.com/s/reg7tviee8telgupc6cccshjet2wqqqh" target="_blank" class="text-uppercase">pi</a>
                    </li>
                    <li>
                        <a href="../page33/index.html" class="text-uppercase">ref</a>
                    </li>
                </ul>
            </div>
        </div>
    </div>

</body>

</html>